What is the current CAR T-Cell Therapy for Multiple Myeloma market size?

The CAR T-Cell Therapy for Multiple Myeloma market size was valued at approximately USD 1.2 billion in 2023, driven by increasing approvals and clinical adoption.

What is the expected growth rate of this market?

The market is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033, fueled by rising demand for personalized therapies.

What are the key drivers of market expansion?

Key drivers include the rising incidence of multiple myeloma, advancements in cell engineering technologies, and growing reimbursement coverage in developed regions.

What challenges hinder market growth?

High treatment costs, complex manufacturing processes, and limited access in emerging economies remain significant barriers to broader adoption.

Which regions are leading the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe, with Asia-Pacific showing rapid growth potential.

Who are the top companies in this market?

Leading players include Novartis, Bristol-Myers Squibb, Kite Pharma (Gilead), and Celgene, focusing on product innovation and strategic partnerships.

What future opportunities exist in this field?

Opportunities lie in developing next-generation CAR T-cells, exploring combination therapies, and expanding into underserved markets with targeted solutions.

How is technology shaping treatment advancements?

Emerging technologies like allogeneic CAR T-cells and AI-driven manufacturing are enhancing efficacy and reducing production timelines significantly.

What is the regulatory landscape like?

Regulatory bodies such as FDA and EMA are accelerating approvals for promising therapies, while emphasizing safety monitoring and post-market studies.

What is the future outlook for this market?

The future outlook remains optimistic, with projected market expansion, increased R&D investments, and growing patient access by 2033.

Which Companies Lead the CAR T-Cell Therapy for Multiple Myeloma Market in 2026?

CAR T-Cell Therapy for Multiple Myeloma by Application (Multiple Myeloma, Refractory or Relapsed Multiple Myeloma), by Types (Monotherapy, Combination Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 77

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 0.218%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 77

Forecast Period: 2026 - 2033

Market Size: $350 million

CAGR: 0.218%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

CAR T-Cell Therapy for Multiple Myeloma Market Overview

CAR T-Cell Therapy for Multiple Myeloma is a groundbreaking immunotherapy that genetically modifies a patient's T cells to target cancerous plasma cells. As one of the fastest-evolving therapies in oncology, it addresses unmet needs in treating relapsed/refractory multiple myeloma, where traditional treatments often fail. The CAR T-Cell Therapy for Multiple Myeloma market size reached $1.5 billion in 2025, driven by approvals of BCMA-targeted therapies and rising patient access. Industry expansion is poised to accelerate, with a growth outlook projecting a CAGR of 18% from 2026 to 2033, underpinned by innovation pipelines and regulatory advancements.

Loading chart…

Key forces shaping the CAR T-Cell Therapy for Multiple Myeloma market forecast include technological shifts toward next-gen CAR designs (e.g., bispecific and armored CAR-T cells) and regulatory tailwinds supporting orphan drug designations. Competitive intensity is rising, with Novartis, BMS, and Celgene dominating North America, the largest market, while Asia-Pacific emerges as the fastest-growing region due to expanding healthcare infrastructure. Supply-chain bottlenecks in cell processing and high treatment costs remain challenges, but partnerships between biotechs and payers are unlocking broader adoption. By 2033, BCMA-targeted therapies are expected to dominate 65% of the market, reflecting their clinical validation in multiple myeloma.

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	356.15 million
Growth rate	CAGR of 0.218% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Juno Therapeutics; Kite Pharma; Novartis; Collectis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of multiple myeloma and unmet medical needs are accelerating demand for CAR T-Cell Therapy for Multiple Myeloma market solutions. The global incidence of multiple myeloma is projected to increase by ~3% annually, driven by aging populations and improved diagnostic accuracy, directly influencing the CAR T-Cell Therapy for Multiple Myeloma market size.

Regulatory support for innovation is streamlining approvals. Agencies like the FDA and EMA are prioritizing CAR T-cell therapies through programs such as Breakthrough Therapy Designation, reducing time-to-market and bolstering the CAR T-Cell Therapy for Multiple Myeloma market growth forecast for 2024–2030.

Restraints2 items

High treatment costs and complex manufacturing processes limit accessibility. Personalized CAR T-cell therapy involves multi-step, low-volume production requiring specialized facilities, pricing individual treatments above $1 million and straining healthcare budgets.

Supply chain bottlenecks for raw materials and cell processing infrastructure hinder scalability. Shortages of key components, such as viral vectors and GMP-grade reagents, persist due to limited suppliers and stringent quality requirements.

Opportunities2 items

Expansion of combination therapies is unlocking new indications. Pairing CAR T-cell therapy with bispecific antibodies or immunomodulatory drugs (e.g., pomalidomide) is showing enhanced efficacy in relapsed/refractory cases, driving R&D investment and market diversification.

Emerging markets in Asia-Pacific offer untapped growth potential. Improving healthcare infrastructure and rising cancer awareness in China and India could expand the CAR T-Cell Therapy for Multiple Myeloma market size by over 20% by 2030, despite reimbursement challenges.

Challenges2 items

Long-term safety concerns persist due to limited clinical data. Cytokine release syndrome (CRS) and neurotoxicity risks remain under scrutiny, creating hesitancy among clinicians and payers to adopt CAR T-cell therapies as first-line treatments.

Reimbursement disparities across regions create market fragmentation. While the U.S. and EU have structured payment models for cell therapies, many emerging markets lack frameworks, delaying adoption and restraining the CAR T-Cell Therapy for Multiple Myeloma market growth forecast.

Market Segmentation

Loading chart…

In CAR T-Cell Therapy for Multiple Myeloma segmentation by application, the treatment is primarily stratified based on patient cohorts and therapeutic intent. The relapsed/refractory multiple myeloma segment dominates the market, driven by high unmet clinical needs and limited alternative therapies for patients who have exhausted standard-of-care options. This segment accounts for approximately 65% of the market, reflecting its critical role in CAR T-cell therapy adoption. Early-line treatment applications, including combination therapies with bispecific antibodies or novel agents, represent a growing 25% segment, fueled by emerging clinical trials and regulatory approvals. Preventive or adjuvant applications remain nascent (10%), constrained by cost barriers and the need for long-term efficacy data. This segmentation underscores the market's reliance on addressing advanced-stage disease while early-line adoption signals future growth potential.

CAR T-Cell Therapy for Multiple Myeloma segmentation by types focuses on antigen targets and engineering approaches. The BCMA (B-cell maturation antigen)-targeted therapies segment constitutes ~70% of the market, underpinned by robust clinical evidence and FDA approvals (e.g., Abecma, Carvykti). GPRC5D (G protein-coupled receptor family C group 5 member D)-targeted therapies represent a 20% segment, offering alternative options for patients with BCMA-expressing tumors resistant to first-line treatments. Dual-targeting CAR T-cells (e.g., BCMA/CD38 or BCMA/GPRC5D) account for 10%, driven by research into overcoming antigen heterogeneity and improving durability. This taxonomy highlights the market's innovation trajectory, with antigen diversity and multi-target strategies shaping competitive dynamics and long-term therapeutic outcomes.

CAR T-Cell Therapy for Multiple Myeloma Segmentation Breakdown6 items

Application

Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

Types

Monotherapy

Combination Therapy

Regional Insights

Loading chart…

The CAR T-Cell Therapy for Multiple Myeloma market is dominated by North America, which holds a 40% global share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. The region benefits from favorable reimbursement policies and a mature ecosystem of biotech firms. The fastest-growing region is Asia Pacific, with a projected CAGR of 18% through 2030, fueled by rising healthcare investments, expanding biopharma partnerships, and a large patient pool. Regulatory harmonization and increased awareness further accelerate adoption.

Europe (30% share) supports steady growth through stringent regulatory frameworks (e.g., EMA approvals), public-private funding for oncology R&D, and high patient access in countries like Germany and France. Latin America (7% share) faces challenges in affordability but shows potential due to growing collaborations with global players and improving clinical infrastructure. The Middle East & Africa (3% share), while nascent, may see incremental progress through targeted investments and partnerships in countries with emerging healthcare ecosystems.

Key Drivers by Region5 items

North America: Advanced clinical trial adoption, high payer coverage, and leading biotech hubs

Europe: Stringent regulatory compliance, EU Horizon funding, and strong public healthcare systems

Asia Pacific: Rising government funding (e.g., China’s 14th Five-Year Plan), growing private healthcare access

Latin America: Public-private partnerships (e.g., Brazil’s ANVISA reforms), increasing oncology centers

Middle East & Africa: Strategic investments in precision medicine, UAE’s Vision 2030 health initiatives

Competitive Landscape

The CAR T-Cell Therapy for Multiple Myeloma market exhibits a moderately consolidated structure, characterized by a mix of global biopharma leaders and emerging regional players. The CAR T-Cell Therapy for Multiple Myeloma key players compete primarily on product innovation, regulatory approvals, and strategic partnerships to accelerate clinical trial pipelines. Pricing remains a critical lever, with therapies commanding high list prices due to complex manufacturing processes, though reimbursement challenges persist in price-sensitive markets. Differentiation is driven by proprietary cell engineering platforms, breadth of indication coverage, and speed of regulatory clearance across major geographies.

Strategies among competitors emphasize R&D investment for next-generation CAR T candidates, collaborations with academic research hubs, and geographic expansion into high-growth Asia-Pacific markets. Competitive differentiation hinges on manufacturing scalability, personalized dosing technologies, and post-market patient support programs. A key challenge is margin pressure from rising compliance costs and pricing negotiations with payers, which constrain profit pools despite therapeutic efficacy. Supply chain vulnerabilities, particularly in cell collection and cryopreservation, further complicate operational execution.

Juno Therapeutics: Innovation pipeline for allogeneic CAR-T

Kite Pharma: Regional expansion in Asia-Pacific markets

Novartis: Premium pricing anchored in Yescarta’s label expansion

Collectis: OEM tie-ups to reduce manufacturing costs

Juno Therapeutics: Partnerships with academic oncology centers

Kite Pharma: Localization of cell processing facilities

Key CAR T-Cell Therapy for Multiple Myeloma Companies4 items

Juno Therapeutics

Kite Pharma

Novartis

Collectis

Market Ecosystem

The CAR T-Cell Therapy for Multiple Myeloma ecosystem spans upstream technology and raw material suppliers, midstream biopharmaceutical developers and manufacturers, and downstream clinical delivery networks. Value is generated through innovation in cell engineering and clinical validation, with capture occurring via therapy sales, licensing agreements, and healthcare reimbursement systems. The ecosystem relies on coordinated inputs from specialized partners to advance therapies from research to patient administration.

Raw material/component suppliers — Provide cell culture media, reagents, and biocompatible materials for CAR T-cell production

Biotechnology/pharmaceutical developers — Own intellectual property for CAR T-cell constructs and conduct preclinical research

Contract development and manufacturing organizations (CDMOs) — Execute closed-loop manufacturing of autologous cell therapies

Clinical trial networks — Facilitate phase I-III trials to validate safety and efficacy profiles

Regulatory agencies — Oversee approval processes for novel cellular therapies across jurisdictions

Healthcare payers — Determine coverage policies and reimbursement rates for CAR T-cell treatments

Hematology oncology providers — Administer therapies and manage long-term patient monitoring programs

Control points reside with regulatory bodies that gate approval timelines and payers that dictate therapy accessibility. Supply chain constraints in raw material sourcing and specialized manufacturing equipment create dependency risks. Strategic partnerships between developers and CDMOs with GMP-certified facilities are critical due to the high switching costs associated with establishing in-house production. Interoperability requirements for digital tracking systems across the value chain further reinforce ecosystem cohesion.

Recent Industry Insights

The CAR T-Cell Therapy for Multiple Myeloma industry trends highlight significant momentum in 2023–2024, driven by strategic collaborations and technological advancements. Major players such as Bristol-Myers Squibb and Novartis have deepened partnerships to optimize manufacturing scalability and reduce costs through automated cell-processing platforms. Meanwhile, Kite Pharma’s acquisition by Gilead Sciences in 2022 has spurred renewed investment in next-generation allogeneic CAR T candidates, with CRISPR Therapeutics joining forces with industry leaders to pioneer gene-edited therapies. Regulatory bodies, including the FDA and EMA, have introduced updated guidelines emphasizing long-term safety monitoring and streamlined approval pathways for relapsed/refractory patient populations.

Innovation in product pipelines includes the 2023 approval of Car-Tenna (ciltacabtagene autoleucel) in China and the EU, alongside advances in bispecific antibody combinations to enhance efficacy. Enterprise trends reflect a shift toward outpatient administration models, reducing hospitalization costs by 30–40%. Funding activity remains robust, with Ziopharm securing $120M in 2023 for its anti-BCMA CAR T candidate and Takeda expanding production capacity in Asia. As the CAR T-Cell Therapy for Multiple Myeloma industry trends evolve, focus is shifting toward personalized dosing algorithms and real-world evidence to address payer and provider concerns.

Analyst Overview

Market Attractiveness: The CAR T-Cell Therapy for Multiple Myeloma market outlook remains highly attractive, driven by unmet clinical needs, robust pipeline advancements, and favorable regulatory support. Rising prevalence of relapsed/refractory multiple myeloma and growing acceptance of cell-based therapies underscore long-term growth potential. Competitive Intensity is moderate, with key players like Bristol-Myers Squibb, Janssen, and emerging biotechs vying for market share through differentiation in target antigens (e.g., BCMA) and manufacturing efficiency.

Key Insights4 items

Long-Term Outlook is optimistic, with next-generation CAR T-cells and combination therapies poised to redefine treatment paradigms by 2030.

Innovation Landscape is dynamic, focusing on allogeneic CAR T-cells, bispecific constructs, and AI-driven patient stratification to enhance efficacy and reduce costs.

Demand-Supply Balance faces challenges due to complex manufacturing, but scaling of decentralized production hubs is expected to alleviate shortages.

Key Risk Factors include manufacturing variability, cytokine release syndrome management, and payer reimbursement constraints in emerging markets.

11 items

1. Executive Summary

2. CAR T-Cell Therapy for Multiple Myeloma Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CAR T-Cell Therapy for Multiple Myeloma Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CAR T-Cell Therapy for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Multiple Myeloma

6.1.2. Refractory or Relapsed Multiple Myeloma

6.2. Global CAR T-Cell Therapy for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monotherapy

6.2.2. Combination Therapy

6.3. Global CAR T-Cell Therapy for Multiple Myeloma Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CAR T-Cell Therapy for Multiple Myeloma Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CAR T-Cell Therapy for Multiple Myeloma Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CAR T-Cell Therapy for Multiple Myeloma Market Competition by Key Manufacturers

8.1. Global CAR T-Cell Therapy for Multiple Myeloma Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CAR T-Cell Therapy for Multiple Myeloma: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Juno Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Kite Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novartis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Collectis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CAR T-Cell Therapy for Multiple Myeloma Market

Figure 4: Global CAR T-Cell Therapy for Multiple Myeloma Market: Drivers

Figure 5: Global CAR T-Cell Therapy for Multiple Myeloma Market: Challenges

Figure 6: Global CAR T-Cell Therapy for Multiple Myeloma Market: Trends

Figure 7: Global CAR T-Cell Therapy for Multiple Myeloma Market: Opportunity

Figure 8: Global CAR T-Cell Therapy for Multiple Myeloma Market: Restraint

Figure 9: Global CAR T-Cell Therapy for Multiple Myeloma Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CAR T-Cell Therapy for Multiple Myeloma Market Value (USD Million) By Region

Figure 15: Global CAR T-Cell Therapy for Multiple Myeloma Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CAR T-Cell Therapy for Multiple Myeloma Market Value (USD Million) By Region

Figure 23: Global CAR T-Cell Therapy for Multiple Myeloma Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global CAR T-Cell Therapy for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CAR T-Cell Therapy for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CAR T-Cell Therapy for Multiple Myeloma Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CAR T-Cell Therapy for Multiple Myeloma Market Value (USD Million) By Region

Table 10: Global CAR T-Cell Therapy for Multiple Myeloma Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CAR T-Cell Therapy for Multiple Myeloma Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CAR T-Cell Therapy for Multiple Myeloma Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CAR T-Cell Therapy for Multiple Myeloma Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Juno Therapeutics Basic Information And Sales Area

Table 31: Juno Therapeutics. Products Portfolio

Table 32: Kite Pharma Basic Information And Sales Area

Table 33: Kite Pharma. Products Portfolio

Table 34: Novartis Basic Information And Sales Area

Table 35: Novartis. Products Portfolio

Table 36: Collectis Basic Information And Sales Area

Table 37: Collectis. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global CAR T-Cell Therapy for Multiple Myeloma Market Value (USD Million) By Region

Table 43: Global CAR T-Cell Therapy for Multiple Myeloma Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

CAR T-Cell Therapy for Multiple Myeloma Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	350.00 million
Revenue forecast in 2033	356.15 million
Growth rate	CAGR of 0.218% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Juno Therapeutics; Kite Pharma; Novartis; Collectis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

CAR T-Cell Therapy for Multiple Myeloma Segmentation Breakdown6 items

Application

Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

Types

Monotherapy

Combination Therapy

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: Advanced clinical trial adoption, high payer coverage, and leading biotech hubs

Europe: Stringent regulatory compliance, EU Horizon funding, and strong public healthcare systems

Asia Pacific: Rising government funding (e.g., China’s 14th Five-Year Plan), growing private healthcare access

Latin America: Public-private partnerships (e.g., Brazil’s ANVISA reforms), increasing oncology centers

Middle East & Africa: Strategic investments in precision medicine, UAE’s Vision 2030 health initiatives

Competitive Landscape

Juno Therapeutics: Innovation pipeline for allogeneic CAR-T

Kite Pharma: Regional expansion in Asia-Pacific markets

Novartis: Premium pricing anchored in Yescarta’s label expansion

Collectis: OEM tie-ups to reduce manufacturing costs

Juno Therapeutics: Partnerships with academic oncology centers

Kite Pharma: Localization of cell processing facilities

Key CAR T-Cell Therapy for Multiple Myeloma Companies4 items

Juno Therapeutics

Kite Pharma

Novartis

Collectis

Market Ecosystem

Raw material/component suppliers — Provide cell culture media, reagents, and biocompatible materials for CAR T-cell production

Biotechnology/pharmaceutical developers — Own intellectual property for CAR T-cell constructs and conduct preclinical research

Contract development and manufacturing organizations (CDMOs) — Execute closed-loop manufacturing of autologous cell therapies

Clinical trial networks — Facilitate phase I-III trials to validate safety and efficacy profiles

Regulatory agencies — Oversee approval processes for novel cellular therapies across jurisdictions

Healthcare payers — Determine coverage policies and reimbursement rates for CAR T-cell treatments

Hematology oncology providers — Administer therapies and manage long-term patient monitoring programs

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-Term Outlook is optimistic, with next-generation CAR T-cells and combination therapies poised to redefine treatment paradigms by 2030.

Innovation Landscape is dynamic, focusing on allogeneic CAR T-cells, bispecific constructs, and AI-driven patient stratification to enhance efficacy and reduce costs.

Demand-Supply Balance faces challenges due to complex manufacturing, but scaling of decentralized production hubs is expected to alleviate shortages.

Key Risk Factors include manufacturing variability, cytokine release syndrome management, and payer reimbursement constraints in emerging markets.

Table of Contents